Study: NCT03620162

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: Prevnar 13™ contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 mL dose given via IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13™
Description: Prevnar 13™ contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 mL dose given via IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13™
Description: Prevnar 13™ contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 mL dose given via IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar 13™
Description: Prevnar 13™ contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each) and 6B (4.4 mcg) in each 0.5 mL dose given via IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: V114 contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose given via IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: V114 contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose given via IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: V114 contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose given via IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114
Description: V114 contains the pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose given via IM injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq™
Description: RotaTeq™ live, pentavalent Rotavirus vaccine given as background treatment via oral solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™
Description: RotaTeq™ live, pentavalent Rotavirus vaccine given as background treatment via oral solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™
Description: RotaTeq™ live, pentavalent Rotavirus vaccine given as background treatment via oral solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™
Description: RotaTeq™ live, pentavalent Rotavirus vaccine given as background treatment via oral solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™
Description: RotaTeq™ live, pentavalent Rotavirus vaccine given as background treatment via oral solution.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pentacel™
Description: Pentacel™ Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine, given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentacel™
Description: Pentacel™ Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine, given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentacel™
Description: Pentacel™ Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine, given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentacel™
Description: Pentacel™ Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine, given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pentacel™
Description: Pentacel™ Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine, given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RECOMBIVAX HB™
Description: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RECOMBIVAX HB™
Description: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RECOMBIVAX HB™
Description: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RECOMBIVAX HB™
Description: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RECOMBIVAX HB™
Description: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HIBERIX™
Description: HIBERIX™ Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIBERIX™
Description: HIBERIX™ Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIBERIX™
Description: HIBERIX™ Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIBERIX™
Description: HIBERIX™ Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIBERIX™
Description: HIBERIX™ Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate), given as background treatment via IM injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: M-M-R™ II
Description: M-M-R™ II (Measles, Mumps, and Rubella Virus Vaccine Live), given as background treatment via subcutaneous (SC) injection in the opposite limb to V114 and Prevnar 13™ administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R™ II
Description: M-M-R™ II (Measles, Mumps, and Rubella Virus Vaccine Live), given as background treatment via subcutaneous (SC) injection in the opposite limb to V114 and Prevnar 13™ administration.